Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Bayer seeks outside advice on litigation as Elliott reveals stake

Published 26/06/2019, 19:10
Updated 26/06/2019, 19:11
Bayer seeks outside advice on litigation as Elliott reveals stake

FRANKFURT (Reuters) - Chemicals giant Bayer (DE:BAYGN), under pressure from activist shareholders, said on Wednesday it has hired an external lawyer to advise its supervisory board and has set up a new committee to resolve a multi-billion dollar glyphosate litigation issue.

Bayer faces massive legal issues in the United States where more than 13,400 plaintiffs allege the company's glyphosate weedkiller Roundup, produced by U.S. unit Monsanto (NYSE:MON), caused cancer and that the company failed to warn about that risk. Bayer denies this.

Bayer said it has hired U.S. lawyer John H. Beisner from Skadden, Arps, Slate Meagher & Flom LLP to advise the Supervisory Board on matters related to the glyphosate litigations, including trial tactics and mediation.

"His appointment is intended to add fresh and independent perspectives to the advice given to the Board of Management," the company said in a statement on Wednesday.

"We are convinced that with his expertise, John H. Beisner will provide very valuable and concrete advice on the ongoing litigation as well as the mediation," Bayer's Chairman Werner Wenning, said in the statement.

Bayer, which acquired Monsanto in a $63 billion (£49.6 billion) deal last year, says studies and regulators have deemed glyphosate and Roundup safe for human use.

Bayer on Wednesday said a new Supervisory Board committee, comprised of eight supervisory board members, will consult with the Board of Management and make recommendations on litigation strategy.

Activist shareholder Elliott Associates revealed on Wednesday that it holds Bayer shares and financial instruments equivalent to 1.1 billion euros ($1.3 billion) worth of Bayer stock. It is the first time that Elliott has acknowledged holding a significant stake in the German company.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Bayer's market value is 52.2 billion euros.

"Elliott welcomes these steps, and is confident that today’s statement marks a step change in Bayer’s approach to addressing the legal challenges currently facing the company," Elliott said in a statement.

Elliott said it believes that the creation of the special committee will provide a new level of oversight and a fresh perspective to a litigation strategy, which it said needs a radical overhaul.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.